Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -70.16%-9.97M | ---- | -127.14%-5.86M | ---- | 84.76%-2.58M | ---- | -715.47%-16.92M | ---- | -2.72%-2.08M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | 15.58%-168K | ---- | -7.57%-199K | ---- | 71.05%-185K | ---- | 36.61%-639K | ---- | 19.49%-1.01M |
| Interest expense - adjustment | ---- | 128.83%254K | ---- | -52.36%111K | ---- | -43.31%233K | ---- | 9.31%411K | ---- | -36.81%376K |
| Impairment and provisions: | ---- | ---- | ---- | 147.21%110K | ---- | -105.60%-233K | ---- | 5,877.78%4.16M | ---- | -102.68%-72K |
| -Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.09M | ---- | ---- |
| -Impairmen of inventory (reversal) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --593K | ---- | ---- |
| -Impairment of trade receivables (reversal) | ---- | ---- | ---- | 158.51%110K | ---- | -418.64%-188K | ---- | 109.67%59K | ---- | -127.09%-610K |
| -Impairment of goodwill | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --538K |
| -Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | -103.17%-45K | ---- | --1.42M | ---- | ---- |
| Revaluation surplus: | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 163.27%62K | ---- | -357.89%-98K |
| -Other fair value changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 163.27%62K | ---- | -357.89%-98K |
| Asset sale loss (gain): | ---- | ---- | ---- | ---- | ---- | -106.06%-2K | ---- | --33K | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | -106.06%-2K | ---- | --33K | ---- | ---- |
| Depreciation and amortization: | ---- | -12.57%4.18M | ---- | 13.96%4.78M | ---- | -30.18%4.19M | ---- | -11.40%6M | ---- | -3.19%6.77M |
| -Amortization of intangible assets | ---- | 0.00%105K | ---- | -5.41%105K | ---- | -21.83%111K | ---- | 15.45%142K | ---- | -6.11%123K |
| Special items | ---- | ---- | ---- | ---- | ---- | -11,025.00%-874K | ---- | 102.62%8K | ---- | -142.36%-305K |
| Operating profit before the change of operating capital | ---- | -437.89%-5.71M | ---- | -292.91%-1.06M | ---- | 107.99%550K | ---- | -291.73%-6.89M | ---- | -53.73%3.59M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | 1,271.43%96K | ---- | 107.07%7K | ---- | -153.85%-99K | ---- | 11.36%-39K | ---- | 91.51%-44K |
| Accounts receivable (increase)decrease | ---- | 184.35%7.89M | ---- | 8,306.06%2.77M | ---- | 134.74%33K | ---- | -102.65%-95K | ---- | -52.09%3.58M |
| Accounts payable increase (decrease) | ---- | -235.89%-3.92M | ---- | 76.64%2.88M | ---- | -5.01%1.63M | ---- | 176.04%1.72M | ---- | 57.54%-2.26M |
| Special items for working capital changes | ---- | -185.85%-2.42M | ---- | 693.47%2.82M | ---- | 30.45%-475K | ---- | -187.34%-683K | ---- | 62.92%782K |
| Cash from business operations | 107.17%396K | -154.69%-4.06M | -13,712.50%-5.53M | 352.44%7.42M | -102.23%-40K | 127.40%1.64M | -52.55%1.8M | -205.89%-5.99M | -46.73%3.79M | -42.79%5.65M |
| Other taxs | ---78K | 52.01%-215K | ---- | -86.67%-448K | -111.86%-125K | 28.14%-240K | 18.06%-59K | -136.82%-334K | -108.26%-72K | 2,934.38%907K |
| Net cash from operations | 105.76%318K | -161.29%-4.27M | -3,248.48%-5.53M | 398.00%6.97M | -109.49%-165K | 122.16%1.4M | -53.22%1.74M | -196.34%-6.32M | -53.45%3.72M | -33.39%6.56M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | -15.58%168K | ---- | 7.57%199K | ---- | -73.11%185K | ---- | -31.75%688K | ---- | -19.49%1.01M |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | 335.29%40K | ---- | 51.43%-17K | ---- | ---35K |
| Decrease in deposits (increase) | ---- | ---- | ---- | ---- | ---6.27M | ---- | ---- | 920.75%55.9M | 554.01%49.31M | -189.56%-6.81M |
| Sale of fixed assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 420.00%78K | ---- | --15K |
| Purchase of fixed assets | 94.22%-10K | -410.34%-1.78M | 49.42%-173K | 99.08%-348K | 99.05%-342K | -1,518.78%-37.75M | -1,773.84%-35.88M | -14.26%-2.33M | -2,523.29%-1.92M | -2,389.02%-2.04M |
| Purchase of intangible assets | ---- | ---34K | ---34K | ---- | ---- | ---332K | ---759K | ---- | ---- | -31.89%-703K |
| Recovery of cash from investments | ---- | ---- | ---- | ---- | ---- | --1.24M | --955K | ---- | ---- | ---- |
| Cash on investment | ---- | ---- | ---- | ---- | ---- | -60.23%-282K | ---390K | 46.67%-176K | ---- | 26.83%-330K |
| Other items in the investment business | 339.02%180K | ---- | -68.70%41K | ---- | -14.38%131K | ---390K | -47.78%153K | ---- | 127.13%293K | ---- |
| Net cash from investment operations | 202.41%170K | -1,002.01%-1.64M | 97.44%-166K | 99.60%-149K | 81.97%-6.48M | -168.88%-37.29M | -175.34%-35.93M | 708.54%54.14M | 534.72%47.68M | -206.58%-8.9M |
| Net cash before financing | 108.57%488K | -186.69%-5.92M | 14.31%-5.69M | 119.01%6.82M | 80.57%-6.64M | -175.05%-35.89M | -166.51%-34.19M | 2,145.47%47.82M | 1,820.18%51.4M | -112.85%-2.34M |
| Cash flow from financing activities | ||||||||||
| New borrowing | --373K | --6.2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Refund | ---- | ---6.22M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -11.82%-331K |
| Issuing shares | --11.67M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Interest paid - financing | 27.63%-55K | -128.83%-254K | -4.11%-76K | 52.36%-111K | 45.52%-73K | 43.31%-233K | 39.09%-134K | -9.31%-411K | -11.68%-220K | 36.81%-376K |
| Issuance expenses and redemption of securities expenses | ---1.07M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other items of the financing business | ---10K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from financing operations | 803.16%9.57M | 7.11%-2.86M | 11.57%-1.36M | 8.44%-3.08M | 55.55%-1.54M | 30.52%-3.36M | -18.56%-3.46M | 28.20%-4.84M | 11.84%-2.92M | 13.18%-6.74M |
| Effect of rate | -511.11%-444K | 262.39%354K | 143.55%108K | -1,382.35%-218K | -4,033.33%-248K | -55.26%17K | -124.00%-6K | -79.79%38K | 208.70%25K | 508.70%188K |
| Net Cash | 242.63%10.06M | -334.38%-8.78M | 13.79%-7.05M | 109.54%3.74M | 78.27%-8.18M | -191.33%-39.26M | -177.66%-37.65M | 573.43%42.98M | 869.51%48.48M | -187.04%-9.08M |
| Begining period cash | -41.05%12.09M | 20.76%20.51M | 20.76%20.51M | -69.79%16.99M | -69.79%16.99M | 325.79%56.23M | 325.79%56.23M | -40.24%13.21M | -40.24%13.21M | 88.68%22.1M |
| Cash at the end | 59.96%21.71M | -41.05%12.09M | 58.53%13.57M | 20.76%20.51M | -53.91%8.56M | -69.79%16.99M | -69.91%18.57M | 325.79%56.23M | 291.23%61.71M | -40.24%13.21M |
| Cash balance analysis | ||||||||||
| Cash and bank balance | ---- | ---- | ---- | ---- | ---- | --16.99M | ---- | ---- | --61.71M | --13.21M |
| Cash and cash equivalent balance | ---- | ---- | ---- | ---- | ---- | --16.99M | ---- | ---- | --61.71M | --13.21M |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Furema Ze Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | Furimazer Certified Public Accountants Limited | -- | Dahua Ma Shiyun Certified Public Accountants Limited | -- | Dahua Ma Shiyun Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.